Angiotensin-converting enzyme inhibition and cardiovascular prevention: More than twenty years of clinical success;Il ruolo dell'inibizione dell'enzima di conversione dell'angiotensina nella prevenzione cardiovascolare: Oltre venti anni, ma non li dimostra

Italian Heart Journal Supplement

Volumn 6, Issue 12, 2005, Pages 769-779

  Borghi, Claudio ^a,b   Cosentino, Eugenio ^a   De Sanctis, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ACE inhibitors; Enalapril; Heart failure; Ischemic heart disease

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL;

ACUTE HEART INFARCTION; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSENSUS; DISEASE SEVERITY; DRUG MECHANISM; ENZYME INHIBITION; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SURVIVAL TIME; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE FUNCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; CAPTOPRIL; CARDIOVASCULAR DISEASES; ENALAPRIL; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION;

EID: 33645016672     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Lenfant C. Shattuck lecture - Clinical research to clinical practice - lost in translation? N Engl J Med 2003; 349: 868-74.
2. Nicholls MG, Charles CJ, Crozier IG, et al. Blockade of the renin-angiotensin system. J Hypertens Suppl 1994; 12: S95-S103.
3. Lyons D, Roy S, O'Bryne S, Swift CG. ACE-inhibition: post-synaptic adrenergic sympatholytic in men. Circulation 1997; 96: 911-5.
4. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-64.
5. Turnbull F, Neal B, Algert C, et al, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-9.
6. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-92.
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
8. Lonn E, Yusuf S, Hoogwerf B, et al, for the HOPE Study and MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICROHOPE substudy. Diabetes Care 2002; 25: 1919-27.
9. Rodrigues EJ, Eisenberg MJ, Pilote L. Effects of early and late administration of angiotensin-converting enzyme inhibitors on mortality after myocardial infarction. Am J Med 2003; 115: 473-9.
10. Ambrosioni E, Borghi C, Magnani B, et al. for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.
11. Fox KM, for the European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
12. Braunwald E, Domanski MJ, Fowler SE, et al, for the PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
13. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
14. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult - summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation, endorsed by the Heart Rhythm Society. Circulation 2005; 112: 1825-52.
15. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
16. Rutherford JD, Pfeffer MA, Moye LA, et al, for the Survival and Ventricular Enlargement (SAVE) Trial Investigators. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. Circulation 1994; 90: 1731-8.
17. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-91.
18. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49-53.
19. Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361: 1843-8.
20. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 1997; 349: 1493-7.
21. Borghi C, Bacchelli S, Ambrosioni E. The use of zofenopril and fosinopril in acute myocardial infarction and carotid artery disease. Am J Hypertens 1994; 7 (Part 2): 96S-101S.
22. Goetz RM. The antiatherogenic potential of blocking the renin-angiotensin system. Expert Opin Investig Drugs 1997; 6: 1651-8.
23. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6.
24. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429-35.
25. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999; 20: 136-9.
26. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
27. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.
28. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-8.
29. Lombardi F, Terranova P. Renin-angiotensin system block and atrial fibrillation. Curr Med Chem 2005; 12: 1331-7.